PEF exits
Korean PE firm to reap hefty returns from US bio investment
By Feb 18, 2021 (Gmt+09:00)
2
Min read
Most Read
S.Korea's LS Materials set to boost earnings ahead of IPO process
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
Galaxy Ring, new foldables set to steal the show at Samsung Unpacked Paris
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
POSCO gears up for carbon-free steelmaking with hydrogen
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
SK Inc. in talks to sell Pharmteco’s US CDMO plant to Novo Nordisk
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
South Korea sets sights on fostering EDA tech to win HBM chip war
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
![(Courtesy of Cognate BioServices)](https://www.kedglobal.com/data/ked/image/2021/02/18/ked202102180011.680x.9.jpg)
Charles River Laboratories International Inc., a US pharmaceutical company, announced the acquisition of Cognate BioServices for approximately $875 million in cash on Feb. 17.
Medivate Partners is the second-largest shareholder of the CDMO company, with a 17.7% stake. EW Healthcare Partners, a US private equity firm, is the majority shareholder of Cognate with an undisclosed stake.
Medivate Partners invested in Cognate in February 2018, along with BlackRock and State General Reserve Fund (SGRF), a sovereign wealth fund in Oman. The Seoul-based PEF made an additional investment in the CDMO firm in January 2020 when the latter acquired Cobra Biologics, a CDMO that provides manufacturing services for plasmid DNA and viral vector.
Established in 2002, Cognate BioServices is the only CMO capable of commercial scale manufacturing of cell therapies, with the world’s largest production capacity. It offers comprehensive manufacturing solutions for cell therapies, as well as for the production of plasmid DNA and other inputs in the CDMO value chain.
Last year, Cognate was prepared to list on South Korea’s junior stock market Kosdaq, which would have made it the first foreign biopharmaceutical company to go public on the Korean stock market. But its shareholders shelved the IPO plan after Charles River showed interest in Cognate late last year. It was Charles River’s third attempt to buy a CDMO.
![(Courtesy of Cognate BioServices)](https://www.kedglobal.com/data/ked/image/2021/02/18/ked202102180012.640x.9.jpeg)
The market for Cognate’s CDMO services – principally cell therapy and plasmid production – is currently estimated at $1.5 billion and expected to grow at least 25% annually over the next five years, it added.
The transaction is expected to close by the end of March.
Medivate Partners, founded in 2012, is a life science investment firm focusing on North Asia and the US. Its portfolio includes WindMIL Therapeutics, a US biotech company developing immune-oncology therapeutics; WCCT Global Inc., a global pharmaceutical contract research organization; and Artiva Biotherapeutics, a US arm of South Korea’s Green Cross Lab Cell Corp.
Write to Chae-Yeon Kim at why29@hankyung.com
Yeonhee Kim edited this article.
More to Read
-
-
Pension fundsKorea’s military fund taps ex-president of Woori Financial as CIO
Jun 28, 2024 (Gmt+09:00)
-
-
Pension fundsKorea's NPS CIO talks with GPIF, GIC execs on asset allocation
Jun 24, 2024 (Gmt+09:00)
-
Foreign exchangeKorea FX authorities, NPS raise currency swap limit to $50 bn
Jun 21, 2024 (Gmt+09:00)
Comment 0
LOG IN